RE:RE:From May 1 NR, regarding Patient #5 and 6Excellent summary Vestor111
vestor111 wrote:
For the new investors - please dig back in the news on the company's website and you will see TLT's story runs far deeper than this very important news. TLT could very well have the biggest breakthu in oncology ever.
Keep in mind TLT is teamed up with Princess Margaret Cancer Center (rated in the top 3 in the world for cancer research) so much of what TLT does or releases is scutanized by one of the highest regarded institutes in the world.
TLT's leading compound - 1433 has shown to be able to treat large hypoxic tumors (large tumors don't need much oxygen which has thwarted treatment for decades - TLT's compound works in low oxygen situtations), it penerates the blood brain barrier (which medical science has spent billions studying due to the great diffcult of getting drugs thru this barrier).
Most major cancers have been lab tested successfully on internationally standardized cancer cell models and a numeroud on standardize animal models - all with great success. The compound has shown an immune response in animal models (immune response have been verified by medical science for PDC compounds so this accept of TLT's compounds have only scratched the surface); a vaccine planned drawning from this immune response - both personalized from the patient's tissues or generic.
Very successful tests on the worst brain cancers and all three large tumor lung cancers (the deadliest and most difficult to treat) in standardized animal models.
GBM tests in animals showed activated could be achieved using very low power X-rays potentially giving far more latitude on activation methods employed over deeper tissue depths particularly in the brain. (Roll the Elysium clip).
Dr Sherri McFarland (future Nobel Prize winner - we all hope (except for the criminal paid trolls)) and her team have created and provided worldwide licensing rights to TLT for many compounds and her patents cover the treatment and combinational compound waterfront like no patent I have ever read (ie she owns this field and many compounds,)
She and her team have recently been granted a $3M+ research grant from the US NIH to study the use of her compounds on melanoma. (So the company has strong research partnership independently pursuing the research into the viability of these compounds.
One of Canada's top lung cancer experts independly verified in models the viability of the compound to treat all 3 major large tumor lung cancers. This researcher is affliated with Canada's Health Network and with PMCC and currently running a trial on an older PDC (originally trialed at PMCC by one of the Dr's overseeing TLT NMIBC trial).
On the hardware side of the equation - the NMIBC DFOC used in the trial - is a one-use device. (Think razor blades potentially need in the hundreds of thousands annually - and many unique device may still be required for various cavity or tubal based cancers - and will likely be one-use
devices.) The device side also has been breaking ground on a wide variety of treatment using cold laser therapy and for cancer treatment - as preliminary research has show to slow tumor growth whil make the tumors more addressable by traditional therapies.
ANd here is a big piece of the magic behind these compounds. The current and next line compounds are Group 8 metals - meaning they "look" like iron to the body. All cancer are iron hogs - they need lots of iron to work their dirty deeds. As such, cancer cells have 16 times (or more) iron receptor cites. So TLT's 1433 compound, for example, has been shown to be shuttled around the body to the various cancer sites where it is absorbed as much as 16 times more than health tissue.
Once absorbed, the compound is activated by specific wavelengths (or X-rays). This process releases Reactive Oxygen Species - which kills the cancer from within the cell. This process is believed to expose the cancer's secrets to the immune system - thus altering the immune system (naturally) to the cancer's presence. (By enhancing this immune system awaking - a vaccine is possible and planned.) One additional point - the compounds and very stable and used in very low concentrations - which is good for shelf life but more importantly, for the overall efficacy and safety of the patient. (Earlier PDCs were unstable and could activae ways that could severally harm the patient.
As Drt Jewwtt, who ran the original Photofrin trial almost 20 years ago said to me (to the effect) "All the problems we found with Phtotofriin appear to have been solved by TLT's compound." Having treated bladder cancer most of his life - this prospect had him very excite.
(Sorry for I am sure many typos and run ons...I am done and want to hit send. I am sure I will regret this but it is what it is...)